Saturday, July 11, 2026

Drug profile · INN

diquafosol sodium

diquafosol sodium (DIQUAS) is a purinergic receptor p2y1 agonist.

PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — diquafosol sodium
Class
Route
Patents
0
Programs
0
Data quality
0.78

Quick answer

diquafosol sodium (DIQUAS) is a purinergic receptor p2y1 agonist.

Key facts

INN diquafosol sodium
Brand DIQUAS
Mechanism Purinergic receptor P2Y1 agonist
Target P2Y purinoceptor 1

Mechanism of action

Purinergic receptor P2Y1 agonist

Primary target: P2Y purinoceptor 1

Approval history

Authority Status Date
PMDA approved

Related & competitor drugs

  1. clopidogrel bisulfate Purinergic receptor P2Y12 antagonist
  2. prasugrel hydrochloride Purinergic receptor P2Y12 antagonist
  3. ticagrelor Blood and blood forming organs (B01)
  4. ticlopidine hydrochloride Purinergic receptor P2Y12 antagonist
  5. cangrelor Blood and blood forming organs (B01)

Frequently asked questions

What is diquafosol sodium?

diquafosol sodium (DIQUAS) is a purinergic receptor p2y1 agonist.

What is the brand name for diquafosol sodium?

DIQUAS is a marketed brand name for diquafosol sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.